AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Tectonic Therapeutic, Inc. Director's Dealing 2022

Feb 4, 2022

33251_dirs_2022-02-04_5e5d5b66-dd04-4560-ad26-4cbe2b86117b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AVROBIO, Inc. (AVRO)
CIK: 0001681087
Period of Report: 2022-02-02

Reporting Person: Ridha Essra (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-02-02	Stock Option (Right to Buy)	$1.84	A	75000	Acquired	2032-02-01	Common Stock (75000)	Direct
2022-02-02	Stock Option (Right to Buy)	$1.84	A	80000	Acquired	2032-02-01	Common Stock (80000)	Direct

Footnotes

F1: 25% of the shares shall vest and become exercisable on February 2, 2023, and the remaining 75% shall vest in equal monthly installments thereafter over a 3 year period.